ampreloxetine is an investigational drug.
There have been 6 clinical trials for ampreloxetine.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 22nd 2019.
The most common disease conditions in clinical trials are Hypotension, Orthostatic, Hypotension, and Pure Autonomic Failure. The leading clinical trial sponsors are Theravance Biopharma and [disabled in preview].
There are eighteen US patents protecting this investigational drug and one hundred and eighteen international patents.